Eupraxia reports Q3 2026 net loss of $15.2 million
Eupraxia reported a $15.2 million net loss for Q3 2026, compared with $6.4 million in Q3 2025. It had $75.2 million in cash and $51.2 million in short-term investments at September 30, 2026, and anticipates funding into the second half of 2028.
Eupraxia reported a Q3 2026 net loss of $15.2M, versus $6.4M in Q3 2025. At September 30, 2026, it had $75.2M in cash and $51.2M in short-term investments; it anticipates funding into the second half of 2028.Material DetailsContext by AI AnalystThis is a quarterly financial update for a clinical-st…